Genomics Services Market By Service Type (Whole Genome Sequencing {WGS}, Whole Exome Sequencing {WES}, Targeted Sequencing, RNA Sequencing, Metagenomics Sequencing, Bioinformatics, Gene Editing, Others), By Technology (Next-Generation Sequencing {NGS}, Polymerase Chain Reaction {PCR}, Microarray, Mass Spectrometry, Gene Editing Tools, Gene Synthesis & Cloning, Proteomics & Metabolomics Platforms), By Application (Cancer Diagnostics, Genetic Disorder Testing, Infectious Disease Detection, Neurological & Cardiovascular Disorders, Reproductive Health, Pharmacogenomics, Drug Development, Others), By End-User (Hospitals & Clinics, Research Institutes, Pharma & Biotech Companies, Contract Research Organizations {CROs}, Diagnostic Labs), Global Market Size, Segmental Analysis, Regional Overview, Company Share Analysis, Leading Company Profiles and Market Forecast, 2025 – 2035.

---

Industry Outlook

The Genomics Services Market accounted for USD 9.87 Billion in 2024 and USD 11.12 Billion in 2025 is expected to reach USD 36.55 Billion by 2035, growing at a CAGR of around 12.64% between 2025 and 2035. Rising demand for personalized medicine, advanced sequencing, and broad applications is driving the genomics market growth. The genomics services market comprises services that involve deciphering the resultant DNA in the form of sequencing, gene editing, bioinformatics, and genetic testing. These service applications are useful in the fields of health, farming, criminology, and science, among others. It has been growing tremendously due to the demand for customized medicine, the enhancement of sequencing, and the enshrinement of genomics. Moreover, the combination of AI and cloud solutions means it is increasingly easy to analyze and obtain data. The industry outlook remains bright and is expected to register growth in the double digits, with major growth being driven by an increase in the number of clinical applications and declining costs of sequencing.

Industry Experts Opinion

"At Illumina, we are committed to driving innovation in the genomics sector and advancing personalized healthcare. By leveraging cutting-edge sequencing technologies and bioinformatics solutions, we aim to provide more precise diagnostics and targeted treatments for a wide range of diseases. Our goal is to make genomic data accessible, actionable, and transformative for patients and healthcare providers worldwide.”

• Francis deSouza, CEO of Illumina.

Report Scope:

Market Dynamics

The growing demand for personalized medicine is increasing the need for genomic-based healthcare solutions.

Discounted genomics services are driven by the rise in the use of personalized medication. This molecular medicine-based approach involves treating patients depending on individual genetic makeup to increase response rates more fully and limit side effects. With today’s concepts in genomics, one can see which gene change is sensitive to a certain kind of treatment. It is most useful in oncology, rare diseases, and chronic diseases such as diabetes and cardiovascular diseases. With the awareness of the concept of personalized medications on the rise, the focus on early diagnosis, testing, and analysis of genomes is also on the rise.

There is a shift of focus toward early diagnosis and then targeting molecular entities in patient-physician relationships. Pharmacogenomics is also becoming increasingly used in pharmaceutical industries for designing better drugs for personalized use. Governments and private sectors have been flocking to fund genomic research to support the rise of this healthcare model. In the end, genetics is gradually shifting from an experimental tool to a corrective element in modern medicine, improving results and minimizing incorrect treatments.

Advancements in next-generation sequencing technologies are boosting the efficiency of genomic services globally.

New developments in NGS technologies are greatly increasing the speed and capacity of genomic operations globally. Whole-genome, exome, or targeted-sequence pairing is possible with NGS, which has transformed genetic analysis on account of its speed, precision, and economical value. These technologies have made analysis faster and have allowed for large-scale studies and faster identification of genomic aspects. Recent clinical uses include cancer subclassification, infection surveillance, and sporadic disease classification. Increased speed and decreased costs make NGS more available for use in research and clinics of different research institutions and healthcare organizations.

Assays are becoming more automated and compatible with bioinformatic software, making data analysis and interpretation less time-consuming. Thus, NGS is building powerful support for precision medicine around the world. Further enhancing the pace of technological development is the relative novelty of sequencing technologies, which has also been proven to present improved performance. This technological advancement is changing the genomics dynamics and helping to create increased demand across many industries.

Limited public awareness reduces demand for genetic testing and personalized healthcare services.

Lack of awareness among the population is one of the biggest challenges that hinders the growth of the genomics services market. Most people remain unaware of the efficiency and use of genetic testing and personalized medicine. This lack of understanding results in non-adherence to genomic tests or rejection of the same, even if it would benefit the patient. Possible reasons include limited understanding of the correct use of genetic data, concern for possible discrimination based on these data, and high costs. Conversely, inadequate awareness created by healthcare providers and governments acts as a barrier to promotion and education.

In the rural and underdeveloped areas, people have much worse access to information than in other areas. As such, patients will miss out on the chance to go for check-ups or follow the right treatment regimens. This means awareness must be created by public health campaigns and educational programs to prevent such behavior. Increasing and agreeing on things that directly explain data security and cost may also help in developing trust. We have to treat this restraint as an issue that must be solved for genomics to find its place in the spheres of healthcare.

Expansion of telemedicine and digital health platforms integrates genomics into routine care.

The advancement in telemedicine and digital applications has opened the door for putting genomics as a recurrent practice in healthcare provision. With virtual visits now an option, clinicians can recommend and coordinate genetic testing, which enhances the availability to patients with a diverse setup, regardless of geographic location. Through the use of digital information, it is easy to share genetic information, which can aid in treatment plans and decisions. The identification of genetic risks at the primary level means that preventive care is supported before any manifestation of symptoms. Moreover, mHealth and mHealth monitoring tools complement genomics for the distinct detection and control of symptoms.

The easy access and time-saving effectiveness of telehealth services enable more people to consider genomics services. Digital infrastructure is being implemented across the healthcare setting, and such innovations are incorporated into healthcare. Similar to this, such collaborations between technological organizations and other genomic service organizations are also fueling this trend. Therefore, the use of telemedicine is advancing to be a critical modality in the provision of individualized care based on genetics.

Emerging markets offer untapped potential due to improving healthcare infrastructure and research funding.

There are solid reasons why emerging markets will be the genomics services firm’s growth driver grey and expanding healthcare infrastructures, and growing research expenditures. Asia, Latin America, and the regions of Mid-East are gradually striving to upgrade their healthcare facility that be conducive for higher diagnostic services like genomics. It is important to know that funding for biotech and life science research is on the rise in these regions, both in government and the private business sector. Consequently, awareness of the principles of personalized medicine and steadily increased the demand for genetic testing and sequencing. With cost-reducing advances in technology, more people in these marketplaces will be able to embrace this technology.

Academic collaborations also engage Institutions of higher learning, and healthcare organizations are exercising innovation. The rise of chronic and genetic diseases in these areas compounds the need for the use of genomic breakthroughs. In addition, the United States possesses a young population with a great acceptance of technology in the delivery of health services. In this respect, the future expansion of genomic services in emerging markets is very promising.

Segment Analysis

Based on the service type, the Genomics Services Market is classified into sequencing services, bioinformatics services, gene editing services, and genetic testing services. Whole-genome sequencing (WGS) and RNA sequencing remain the largest and fastest-growing services due to the continued development of next-generation sequencing technologies and increasing use in such fields as personalized medicine and diagnostics. Bioinformatics services are on the rise, as with the continued growth of genomics, a service such as data interpretation or software platforms may be required.

Gene editing technologies, especially CRISPR-Cas9, have rapidly cropped up in multiple areas of research and clinical use, and a wide spectrum of genetic alteration possibilities. Genetic testing services continue to expand due to a growing interest in prenatal, cancer, and carrier screening tests, in particular, as consumers become more sensitive to matters of early diagnosis and prevention. Combined, these service kinds are increasingly supporting advanced solutions in the healthcare, agriculture, and research fields and applications of genomics.

Based on the application, the Genomics Services Market is classified into cancer diagnostics, personalized medicine, agrigenomics, forensic & legal applications, and biotechnology & pharmaceutical research. Cancer Diagnostics has a large market share, and molecular-based diagnostic services include the testing of genes to identify diseases such as cancer, genetic disorders, and many others. Personalized medicine is a fast-developing field, partially due to the requirements for genetic tracking, especially in pharmacogenomics and cancer therapies.

Agrigenomics is evolving increasingly with the help of genomics for raising crop productivity, crop quality, disease tolerance, and livestock selection. Forensically, DNA profiling is used in criminal investigations, while it is used in determining parentage in legal cases. In addition, the pharma and biotech industries leverage genomics in drug discovery, identification of biomarkers, and development of genetic objectives that inform therapies and precision medicine.

Regional Analysis

The North American Genomics Services Market is the fastest growing due to increased investments in healthcare systems, strong research programs, and the increasing need for personalized medicine. The largest market is the United States, with powerful biotech and pharma sectors, an abundance of research infrastructure, and high usage of NGS technologies. It is also a region of strong healthcare, federal grants for genetic research, and a relatively high level of genetic literacy among the populace. In particular, market giants like Illumina, Thermo Fisher, and 23andMe are situated in North America, thus boosting the market advancements even further. North America is expected to retain its position as the most dominant market in the global market of precision medicine and genomics applications in diagnosing cancer and rare diseases affecting the population.

The Asia-Pacific Genomics Services Market is the fastest growing due to rising access to healthcare services, research activity, and growth in personalized medicine. China and India, in particular, have been making breakthroughs in genomics, and a host of developments have been made in both the public and private sectors to encourage genomics research. The growing biotech and pharmaceutical sectors in these regions are now driving the demand for genomics services such as diagnostics, testing, and drug development. In addition, there is increasing awareness of the uses of genomic technologies and the population base and size of the populations that require tailored medicine and treatment. Enhancement of healthcare expense restraints and lenient government policies are also driving growth in this region for the genomics market.

Competitive Landscape

The Genomics Services Market is very fragmented, and there is intense competition among players spread across various market segments in the genomics services market. Currently, Illumina Inc., an American biotechnology company, is the market leader, providing a range of sequencing systems and bioinformatics software. Another large company based in the United States is Thermo Fisher Scientific, which offers numerous kinds of genomic solutions sequencing, bioinformatics, and functional genomics, strengthened by the acquisition of Life Technologies Corporation. QIAGEN is a German company that specializes in a wide range of solutions for genomic analysis targeting the research and clinical sectors. BGI Group is one of the biggest sequencing companies in China, providing extensive genomics solutions. Eurofins Scientific is based in Luxembourg and has established laboratories all over the world that help in identifying and supporting diverse industries, inclusive of genomics.

10x Genomics, located in the United States of America, is focused on offering single-cell analysis and spatial genomics that provide intricate tools for analyzing genetics. In the oncology space, Guardant Health, Natera, and Exact Sciences are key competitors, all testing for cancer in blood. Furthermore, the direct-to-consumer genotyping company from the USA, 23andMe, provides ancestry and genetic health risk information. The market is also seeing entrants such as Nebula Genomics, which provides whole genome sequencing services with personalized privacy and ownership of data. This diverse competition is evidence that the genomics services market is quite competitive, especially because firms are harnessing more technologies and entering into other strategic partnerships.

Genomics Services Market, Company Shares Analysis, 2024

To explore in-depth analysis in this report - Request Sample Report

Recent Developments:

• In April 2025, OpenSNP, an open-source platform for sharing genetic information, announced that it was shutting down. The closure was due to concerns about data misuse and the bankruptcy of 23andMe. The platform highlighted the need for stronger privacy protection frameworks as genomic research and data sharing practices continued to evolve.
• In November 2023, Fabric Genomics collaborated with DNAnexus and Oxford Nanopore Technologies for the deployment of CLIA/CAP labs in pediatric and neonatal ICU’s. The labs will use Oxford Nanopore’s platforms to study genetic disorders in infants.

Report Coverage:

By Service Type

• Whole Genome Sequencing (WGS)
• Whole Exome Sequencing (WES)
• Targeted Sequencing
• RNA Sequencing
• Metagenomics Sequencing
• Bioinformatics
• Gene Editing
• Others

By Technology

• Next-Generation Sequencing (NGS)
• Polymerase Chain Reaction (PCR)
• Microarray
• Mass Spectrometry
• Gene Editing Tools
• Gene Synthesis & Cloning
• Proteomics & Metabolomics Platforms

By Application

• Cancer Diagnostics
• Genetic Disorder Testing
• Infectious Disease Detection
• Neurological & Cardiovascular Disorders
• Reproductive Health
• Pharmacogenomics
• Drug Development
• Others

By End-User

• Hospitals & Clinics
• Research Institutes
• Pharma & Biotech Companies
• Contract Research Organizations (CROs)
• Diagnostic Labs

By Region

North America

• U.S.
• Canada

Europe

• U.K.
• France
• Germany
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Singapore
• Rest of Asia Pacific

Latin America

• Brazil
• Argentina
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC Countries
• South Africa
• Rest of the Middle East & Africa

List of Companies:

• Illumina, Inc.
• Thermo Fisher Scientific, Inc.
• QIAGEN N.V.
• BGI Group
• Eurofins Scientifi
• 10x Genomics, Inc.
• Guardant Health, Inc.
• Natera, Inc.
• Exact Sciences Corporation
• 23andMe, Inc.
• Agilent Technologies, Inc.
• HudsonAlpha Institute for Biotechnology
• Gene by Gene, Ltd.
• Pacific Biosciences of California, Inc.
• Oxford Nanopore Technologies, Ltd.

Frequently Asked Questions (FAQs)